Transgender women are still at risk for prostate cancer. A new study led by Cedars-Sinai Cancer investigators, published in the peer-reviewed Journal of the American Medical Association, concludes that current screening guidelines could miss early-stage prostate cancer in transgender women on hormone therapy.